• 1
    Taylor JF, Templeton AC, Vogel CL, et al. Kaposi's sarcoma in Uganda: a clinico-pathological study. Int J Cancer 1971;8:12235.
  • 2
    Thijs A. Kaposi's angiosarcomatosis in the Belgian Congo & Ruanda-Urundi. Ann Soc Belg Med Trop (1920) 1957;37:295308.
  • 3
    Cook-Mozaffari P, Newton R, Beral V, et al. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer 1998;78:15218.
  • 4
    Shiels MS, Pfeiffer RM, Hall HI, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980–2007. JAMA 2011;305:14509.
  • 5
    Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 2010;116:550716.
  • 6
    Green EC, Halperin DT, Nantulya V, et al. Uganda's HIV prevention success: the role of sexual behavior change and the national response. AIDS Behav 2006;10:33546.
  • 7
    Halperin DT, Mugurungi O, Hallett TB, et al. A surprising prevention success: why did the HIV epidemic decline in Zimbabwe? PLoS Med 2011;8:e1000414.
  • 8
    Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010;103:41622.
  • 9
    WHO. Progress on global access to HIV antiretroviral therapy: a report on “3 by 5” and beyond. Geneva, Swizerland: WHO, 2006.
  • 10
    Sanders CJ. Kaposi's sarcoma in retrospect. Genitourin Med 1997;73:57174.
  • 11
    Parkin DM, Wabinga H, Nambooze S, et al. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 1999;13:256370.
  • 12
    UNAIDS, WHO. 2008 Report on the global AIDS epidemic. UNAIDS WHO 2010 [cited 2010]; Available from: URL:
  • 13
    Fritz A, Pajares JM, Jack A, et al. International classification of diseases for oncology, 3rd ed. Geneva, Swizerland: WHO, 2000.
  • 14
    Parkin DM, Vizcaino AP, Skinner ME, et al. Cancer patterns and risk factors in the African population of southwestern Zimbabwe, 1963–1977. Cancer Epidemiol Biomarkers Prev 1994;3:53747.
  • 15
    Chokunonga E, Levy LM, Bassett MT, et al. Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993–1995. Int J Cancer 2000;85:549.
  • 16
    Wabinga H, Nambooze S, Amulen M. Uganda, Kampala Cancer Registry (KCR) 2008. Kampala Cancer Registry 2010 [cited 2010 Dec 1]; Available from: URL:
  • 17
    CI5 I-IX Cancer Incidence in Five Continents Volumes I to IX. IARC 2012 [cited 2012 Jul]; Available from: URL:
  • 18
    Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in five continents. Lyon: IARC, 2008.
  • 19
    Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon, France: IARC, 1999.
  • 20
    Šidàk Z. Rectangular confidence region for themeans of multivariate normal distributions. J Am Statis Asso 1967;62:62633.
  • 21
    Statistical Research and Applications Branch. Joinpoint Regression Program. In: National Cancer Institute, ed. Bethesda, MD: National Cancer Institute, 2008.
  • 22
    Clegg LX, Hankey BF, Tiwari R, et al. Estimating average annual per cent change in trend analysis. Stat Med 2009;28:367082.
  • 23
    JoinPoint Regression Program [computer program]. Version 3.5 Surveillance Research Program National Cancer Institute; 2011.
  • 24
    Sissolak G, Mayaud P. AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health 2005;10:98192.
  • 25
    Serwadda D, Mugerwa RD, Sewankambo NK, et al. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet 1985;2:84952.
  • 26
    Okware SI. Towards a national AIDS-control program in Uganda. West J Med 1987;147:7269.
  • 27
    Hiza PR. International co-operation in the national AIDS control program. In: Fleming A, ed. Proceeding of the First International Conference on the Global Impact of AIDS. New York, USA, 2010. 2339.
  • 28
    UNAIDS WHO. UNAIDS report on the global AIDS epidemic 2010. Geneva, Swizerland; 2010.
  • 29
    Vanni T, Sprinz E, Machado MW, et al. Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives. Cancer Treat Rev 2006;32:44555.
  • 30
    Mosam A, Uldrick TS, Shaik F, et al. An evaluation of the early effects of a combination antiretroviral therapy programme on the management of AIDS-associated Kaposi's sarcoma in KwaZulu-Natal, South Africa. Int J STD AIDS 2011;22:6713.
  • 31
    Mosam A, Shaik F, Uldrick TS, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr 2012;60:1507.
  • 32
    UNAIDS/WHO. UNAIDS World AIDS Day Report 2011. Geneva, Swizerland: UNAIDS/WHO; 2011.
  • 33
    Stoneburner RL, Low-Beer D. Population-level HIV declines and behavioral risk avoidance in Uganda. Science 2004;304:7148.
  • 34
    Shelton JD, Halperin DT, Nantulya V, et al. Partner reduction is crucial for balanced “ABC” approach to HIV prevention. BMJ 2004;328:8913.
  • 35
    Cohen S. Promoting the “B” in ABC: its value and limitations in fostering reproductive health. The Guttmacher Report on Public Policy; 2004 Oct 1, vol. 7, p. 4.
  • 36
    Fenton L. Preventing HIV/AIDS through poverty reduction: the only sustainable solution? Lancet 2004;364:11867.
  • 37
    Singh S, Darroch JE, Bankole A. A, B and C in Uganda: the roles of abstinence, monogamy and condom use in HIV Decline. Occasional Report No. 9. New York: Allan Guttmacher Inst, 2003.
  • 38
    International Programs Center PDUSCB. HIV/AIDS Surveillance Data Base: Uganda. International Programs Center,Population Division, U S Census Bureau 2000 June [cited 2010 Dec 1]; Available from: URL:
  • 39
    Biryahwaho B, Dollard SC, Pfeiffer RM, et al. Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population-based sample in Uganda. J Infect Dis 2010;202:134753.
  • 40
    Dollard SC, Butler LM, Jones AM, et al. Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the “Kaposi's sarcoma belt”. Int J Cancer 2010;127:2395401.
  • 41
    Pfeiffer RM, Wheeler WA, Mbisa G, et al. Geographic heterogeneity of prevalence of the human herpesvirus 8 in sub-Saharan Africa: clues about etiology. Ann Epidemiol 2010;20:95863.
  • 42
    Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:18659.
  • 43
    IARC. International Agency for Research on Cancer (IARC). Kaposi's sarcoma herpesvirus/human herpes virus 8. Lyon, France: IARC, 1997.
  • 44
    Bouvard V, Baan R, Straif K, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009;10:3212.
  • 45
    Safai B, Mike V, Giraldo G, et al. Association of Kaposi's sarcoma with second primary malignancies: possible etiopathogenic implications. Cancer 1980;45:14729.